EP0971916A1 - N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittel - Google Patents

N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittel

Info

Publication number
EP0971916A1
EP0971916A1 EP98914932A EP98914932A EP0971916A1 EP 0971916 A1 EP0971916 A1 EP 0971916A1 EP 98914932 A EP98914932 A EP 98914932A EP 98914932 A EP98914932 A EP 98914932A EP 0971916 A1 EP0971916 A1 EP 0971916A1
Authority
EP
European Patent Office
Prior art keywords
group
formula
compound
straight
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98914932A
Other languages
English (en)
French (fr)
Inventor
Jean-Michel Altenburger
Gilbert Lassalle
Daniel Galtier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of EP0971916A1 publication Critical patent/EP0971916A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to and derivatives of 5 N- (arginyl) benzenesulphonamide, their preparation and their therapeutic application.
  • R 3 represents either a hydrogen atom or a (C 1 -C 5 ) straight or branched alkyl group, or a group -C0R 5 where R 5 is a (C 1 -C 4 ) straight or branched alkyl group, - (CH 2 ) n OCH 3 , -CH 2 0 (C 2 H 4 0) n CH 3; - (CH 2 ) n CF 3 , - (CH 2 ) n 0H (n equal 1 to 4), either a group -S0 2 R 6 , or a group -CONHR 6 , or a group
  • the ratio (x: y) represents the ratio (acid: base).
  • reaction medium The temperature of the reaction medium is allowed to return to ambient temperature and stirring is continued for 18 hours at this temperature. Evaporated under reduced pressure and the aqueous phase is extracted with 2 times 300 ml of ethyl acetate. The organic phases are combined and washed with 100 ml of a saturated sodium chloride solution. It is dried over sodium sulfate and concentrated under reduced pressure. The residue thus obtained is purified by chromatography on a column of silica gel, eluting with a cyclohexane: ethyl acetate mixture (9: 1).
  • the residue is taken up in 150 ml of ethyl acetate and washed successively with 100 ml of an aqueous 0.1N hydrochloric acid solution, 50 ml of a saturated solution of sodium hydrogencarbonate and 50 ml of a saturated solution of sodium chloride. It is dried over sodium sulfate and concentrated under reduced pressure.
  • the residue is purified by chromatography on a column of silica gel, eluting with a dichloromethane: methanol mixture (98: 2).
  • the mixture is heated at 50 ° C. for 0.5 hour under a pressure of 0.35 MPa (50 psi) a mixture of 0.75 g (0.9 mmol) of (S) - [4- [(4-ethylpiperidin- l-yl) carbonyl] -4- [[[2 '-fluoro-2- [(1- oxopropyl) amino] [1,1' -biphenyl] -3-yl] sulfonyl] amino] butyl] [imino [[ (phenylmethoxy) carbonyl] amino] methyl] phenylmethyl carbamate and 0.8 g of 10% palladium on carbon in 10 ml of water and 10 ml of acetic acid.
  • the temperature of the mixture is allowed to return to ambient temperature, it is stirred for 18 hours at this temperature and concentrated under reduced pressure.
  • the residue is taken up in 100 ml of 7 ethyl acetate and washed successively with twice 50 ml of 0.5N hydrochloric acid, 50 ml of a saturated solution of sodium hydrogen carbonate and 50 ml of a saturated sodium chloride solution. It is dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • the residue is taken up in 50 ml of tetrahydrofuran and treated for 15 minutes at 0 ° C. with a stream of gaseous ammonia. The temperature is allowed to return to room temperature, stirring is continued for 2 hours and concentrated under reduced pressure.
  • the temperature of the reaction medium is allowed to return to ambient temperature, stirring is continued for 15 hours at this temperature and concentration is carried out under reduced pressure.
  • the residue is taken up in 100 ml of ethyl acetate, washed twice with 50 ml of 1N hydrochloric acid and then with 50 ml of a saturated solution of sodium chloride, dried over sodium sulfate, filtered. and concentrated under reduced pressure.
  • the temperature of the reaction medium is allowed to return to ambient temperature, stirring is continued for 16 hours at this temperature and concentration is carried out under reduced pressure.
  • the residue is taken up in 100 ml of ethyl acetate, washed successively with 30 ml of 1N hydrochloric acid, 20 ml of water, 30 ml of a saturated solution of sodium hydrogen carbonate and then with 20 ml of saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • the temperature of the mixture is allowed to return to ambient temperature and stirring is continued for 18 hours at this temperature.
  • the reaction medium is cooled to 0 ° C., acidified to pH 2 with a 12N aqueous hydrochloric acid solution and then neutralized with a solution of sodium hydrogencarbonate before adding 2.4 g (11 mmol) of bis (1, 1-dimethylethyl) dicarbonate dissolved in 15 ml of methanol.
  • the temperature of the mixture is allowed to return to room temperature, stirring is continued for 18 hours at this temperature and concentrated under reduced pressure.
  • the residue is taken up in 200 ml of ethyl acetate, washed with 50 ml of a saturated sodium chloride solution, dried over sodium sulphate and concentrated again under reduced pressure.
  • the residue thus obtained is purified by chromatography on a column of silica gel, eluting with a cyclohexane: ethyl acetate mixture (7: 3).
  • the reaction medium is left under stirring at this temperature for 6 hours and concentrated under reduced pressure.
  • the residue is purified by chromatography on a column of silica gel, eluting with a cyclohexane: ethyl acetate mixture (1: 1).
  • reaction medium The temperature of the reaction medium is allowed to return to ambient temperature, stirring is continued for 30 minutes at this temperature and evaporated to dryness.
  • the residue is taken up in 250 ml of toluene and evaporated to dryness. It is taken up in 200 ml of toluene and evaporated to dryness.
  • the residue is purified by chromatography on a column of silica gel, eluting with a dichloromethane: methanol mixture (99.5: 0.5).
  • HC1 corresponds to a hydrochloride and the ratio between brackets is the ratio (help: base); the absence of any mention means that the compound is in the base form.
  • - c 0.2; methanol except for compounds n ° 11, 12, 13, 14, 18, 19, 21, 23, 25, 30, 32, 33, 34, 41 and 42,
  • mice Male CD rats weighing 150 to 200 g are treated with the test compound or with the vehicle, i.v., orally or subcutaneously. Then the animals are anesthetized with Nembutal TM (60 mg / kg; 0.1 ml / kg), the blood is taken on 3.8% trisodium citrate (1 vol / 9 vol of blood) at the retro sinus orbital and the plasma is prepared by centrifugation at 3600 g for 15 minutes at room temperature. 200 ⁇ l of plasma are then incubated at 37 ° C. with 200 ⁇ l of a human thrombin solution, the final concentration of human thrombin being 0.75 NIH units / ml and the coagulation time is noted. The anticoagulant effect is expressed by the dose which increases the coagulation time by 100%. They inhibit the coagulation of rat plasma at doses of 0.01 to 5 mg / kg i.v. They are also active by the oral and subcutaneous routes.
  • Nembutal TM 60 mg / kg;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98914932A 1997-03-20 1998-03-17 N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittel Withdrawn EP0971916A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9703392 1997-03-20
FR9703392A FR2761065B1 (fr) 1997-03-20 1997-03-20 Derives de n-(arginyle)benzenesulfonamide, leur preparation et leur application en therapeutique
PCT/FR1998/000532 WO1998042700A1 (fr) 1997-03-20 1998-03-17 Derives de n-(arginyl)benzenesulfonamide et leur utilisation comme agents antithrombotiques

Publications (1)

Publication Number Publication Date
EP0971916A1 true EP0971916A1 (de) 2000-01-19

Family

ID=9505004

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98914932A Withdrawn EP0971916A1 (de) 1997-03-20 1998-03-17 N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittel

Country Status (6)

Country Link
EP (1) EP0971916A1 (de)
AR (1) AR012096A1 (de)
AU (1) AU6924398A (de)
FR (1) FR2761065B1 (de)
WO (1) WO1998042700A1 (de)
ZA (1) ZA982355B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793418B1 (fr) * 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee
CN105707076B (zh) * 2014-12-05 2018-12-14 沈阳中化农药化工研发有限公司 除草组合物及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1131621A (en) * 1977-01-19 1982-09-14 Shosuke Okamoto N.sup.2-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
FR2735469B1 (fr) * 1995-06-13 1997-07-11 Synthelabo N2-(arylsulfonyl)-l-arginylpiperidin-2-carboxylates, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9842700A1 *

Also Published As

Publication number Publication date
FR2761065A1 (fr) 1998-09-25
AU6924398A (en) 1998-10-20
WO1998042700A1 (fr) 1998-10-01
FR2761065B1 (fr) 2000-03-03
ZA982355B (en) 1998-09-22
AR012096A1 (es) 2000-09-27

Similar Documents

Publication Publication Date Title
TW397825B (en) Aroyl-piperidine derivatives
EP1497274B1 (de) Terphenylderivate, deren herstellung und zusammensetzungen, die diese enthalten
EP1499589B1 (de) N-¬phenyl(piperidin-2-yl)methyl|benzamidderivate,verfahren zu ihrer herstellung und ihre therapeutische anwendung
EP0307303B1 (de) 1-[(2-Pyrimidinyl)-aminoalkyl]-piperidine, deren Herstellung und Verwendung als Heilmittel
EP0090733B1 (de) Disubstituierte Polymethylen-Imine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
FR2786482A1 (fr) Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique
JP2001513767A (ja) メタロプロテアーゼ阻害剤としての逆ヒドロキサメート誘導体
CN102811998A (zh) 新的亲环素抑制剂及其用途
FR2659323A1 (fr) Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
EP0360685B1 (de) 1-[(Diarylmethoxy)alkyl]-pyrrolidine und -piperidine, Verfahren zu ihrer Herstellung und Arzneimittel, die sie enthalten
EP1960387B1 (de) Isochinolin- und benzo[h]isochinolin-derivate, herstellung und therapeutische verwendung davon als antagonisten des histamin-h3-rezeptors
EP0004494B1 (de) 1,3-Dihydro-3-(1-(2-(2,3-dihydro-1,4-benzodioxin-2-yl)2-hydroxy-äthyl)piperidin-4-yl)2H-indol-2-on Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zubereitungen
FR2758329A1 (fr) Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
FR2751650A1 (fr) Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
EP0301936B1 (de) Piperidin-Derivate, deren Herstellung und deren Verwendung als Heilmittel
DE69813886T2 (de) Naphthalin derivate
EP0718307A2 (de) 1-Oxo-2-(phenylsulfonyl-amino)-pentylpiperidine Derivate, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
FR2753970A1 (fr) Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
EP0971916A1 (de) N-(arginyl)benzensulfonamidderivate und ihre verwendung als antithrombotische mittel
EP1385858B1 (de) Neue 5-thio-ss-d-xylopyranosidderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen und deren therapeutische verwendung
FI105270B (fi) Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi
FR2783521A1 (fr) Derives de n-(arginyl) benzenesulfonamide, leur preparation et leur application en therapeutique
EP0946517A1 (de) N-(imidazolylbutyl)-phenylsulfonamidderivate mit antithrombotischer aktivität
FR2681320A1 (fr) Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
EP0522914A1 (de) 2-Piperidinylpyrimidin-4-Carboxamidderivate, deren Herstellung und deren Verwendung als Heilmittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011002